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The ImpacT of emeRgIng maRkeTS on The 
phaRmaceuTIcal InduSTRy
M. Tannoury; and Z. Attieh
American University of Science and Technology, Beirut, Lebanon
Emerging markets are considered nowadays the “Promised Land” 
for pharmaceutical industries. Although a clear-cut definition of 
these markets is not yet available, Forbes magazine along with 
other economists define them as developing prosperous countries. 
In these countries, an investment is expected to result in higher 
income despite the high risks. Qualifying a market as emerging is 
not solely based on the country’s economic status but rather on a 
series of criteria making the definition relative to each. Jim O’Neill, 
retired chairman of Goldman Sachs Asset Management, coined 
the names of the 2 leading economies of emerging markets into 
2 acronyms. BRICS countries (Brazil, Russia, India, China, and 
later South Africa) emerged first and were followed years later by 
MIST countries (Mexico, Indonesia, South Korea, and Turkey) as 
the second wave of tiers countries joining emerging markets. In the 
last 5 years, sales of pharmaceuticals in BRICS and MIST mar-
kets doubled, reaching a share of ~20% globally. This shift stems 
from the huge populations of the concerned societies, an increasing 
prosperity, and life expectancy. In addition, companies are suffering 
from a flattened growth rate in developed markets, the expiration 
of > 40% of patents leading to the up-selling of cheaper generic 
drugs, and the existing tight regulations. However, Big Pharma needs 
to be cautioned regarding these emerging markets. Pharmaceutical 
companies wanting to expand in these emerging opportunities have 
to tailor their strategies according to the developing pace of each 
country. These communities are in need of drugs against infectious 
and communicable diseases such as sexually transmitted diseases. 
They are ready-to-exploit territories for the innovative products of 
pharmaceuticals. However, with the increase in wealth and longevity, 
a change of lifestyle is slowly taking place accompanied by a shift in 
the disease trends. A disproportionately fast rise in the incidence of 
noncommunicable diseases such as cardiovascular illnesses, diabetes, 
and cancers is noticed in emerging markets, mimicking the pattern of 
their Western counterparts. The incidence of diabetes and oncologic 
diseases is expected to grow by ≥ 20% in the next 5 years. This could 
be viewed as a mixed blessing, as pharmaceutical industries will 
be able to sell their global products in these new markets as well. 
Industries face challenges to conquer emerging markets grouped 
into 3 categories: infrastructure development, cost-containment poli-
cies, and value-driven drug evaluation. To overcome these hurdles, 
new strategies need to be adopted by pharmaceutical companies. 
Adequate tailoring and gain in market are among the top strategies 
to be considered.
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Background: In hospitals, clinical data are often scattered across 
multiple databases and application systems due to decentralized clini-
cal information system architectures. Consequently, the reuse of once 
collected data for secondary purposes as data analytics and data 
mining is considered a challenging task.1 Enterprise Data Warehouses 
(EDW) have been established at several medical centers to overcome 
typical obstacles to data reuse such as proprietary data models, ter-
minologies, lack of governance, and more. However, the complexity 
and high rate of change of the clinical domain and medical data 
cause high costs for maintenance of data models and the provision 
of data to researchers.2 Detailed Clinical Models might help to better 
manage these domain-specific challenges by introducing formal and 
computable methods to represent clinical content models to data 
warehousing.3 One example of a Detailed Clinical Model approach 
is openEHR, a specification of an open, interoperable electronic 
health record.4 Although the use of openEHR in the context of a 
health information exchange is well established, there is still a lack 
of evidence regarding its feasibility to represent and integrate legacy 
data into EDWs.
Methods: We chose the domain of intensive care medicine to investi-
gate if openEHR can meet a diverse set of requirements to represent 
and help integrate clinical data that are stored in application systems. 
At Hannover Medical School, 2 independent patient data manage-
ment systems (COPRA and m.life) are incorporated at the intensive 
care wards. We identified a test set of 8 clinical concepts that are 
commonly used in these systems: blood pressure, body temperature, 
pulse, heart rate, indirect oximetry, Braden Scale, Glasgow Coma 
Scale, and ventilation. For each of these measurements, we intended 
to obtain an openEHR Archetype (a formal content model of a clini-
cal concept) or to create a new one. Subsequently, Archetypes were 
used to create a Template, which can be thought of as a use case-
specific document. For the task of data integration and mapping, we 
used a combination of Microsoft SSIS, Altova MapForce 2014, and 
the Template Document Schema approach.5
Results: We obtained 7 Archetypes from the Clinical Knowledge 
Manager, the public content model repository of the openEHR 
Foundation. Because no ventilation Archetype was available at the 
time of this work, we created a new Archetype. We found it possible 
to map most types of legacy data from the given application systems 
to openEHR Templates. The representation and mapping of Braden 
Scales and Glasgow Coma Scales data were straightforward. By con-
trast, the mapping of continuous sensor data (eg, blood pressure 
measurements generated by sensors) required the arbitrary segmenta-
tion of values into multiple documents. For this purpose, we chose 
a 24-hour interval. When integrating ventilation data, we found a 
high number of corresponding variables in the source systems (~300). 
Because available resources were limited, we decided to create a first 
draft version of the ventilation Archetype that only represents data 
elements of the most important parameters. In coordination with a 
clinical expert, 30 data items were identified and then modeled in 
the archetype.
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Conclusions: Essentially, we found it possible to use Archetypes 
and Templates to integrate a test set of intensive care data from 2 
systems. By applying the openEHR approach for data modeling and 
integration, detailed clinical models can be used for tasks such as 
automated constraint checking, error reporting, data persistence, and 
querying. Although medical scores such as the Glasgow Coma Scale 
were a good fit for openEHR, voluminous data such as vital signs 
and ventilation data needed some workarounds to work properly. 
Especially, the demand of archetypes to be explicit about the meaning 
of each data element might be problematic in some data integration 
scenarios. On the one hand, this might be considered an advantage, 
as it forces EDW developers and system analysts to work thoroughly. 
On the other hand, this constraint might prevent pragmatic solutions 
when a fast integration cannot be achieved or interpretation of data 
can be conducted by the end-users. Although this work illustrates 
some of the strengths and restrictions of the openEHR approach for 
data integration tasks, our methodology is limited by the number 
of used clinical concepts. A possible next step is the investigation of 
the implications of openEHR-based information retrieval and the 
semantic interpretation of data.
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Background: The medical devices sector helps save lives by provid-
ing innovative health care solutions regarding diagnosis, prevention, 
monitoring, treatment, and alleviation. Medical devices are classified 
into 1 of 3 categories in the order of increasing risk: Class I, Class II, 
and Class III.1 Medical devices are distinguished from drugs for 
regulatory purposes based on mechanism of action. Unlike drugs, 
medical devices operate via physical or mechanical means and are 
not dependent on metabolism to accomplish their primary intended 
effect.2,3
Objectives: This study focused on regulations and differences in med-
ical device and pharmaceutical drug development. It also highlighted 
the unique challenges faced while doing medical device development.
Methods: A US Food and Drug Administration and European 
Medicines Agency website search was conducted to determine cur-
rent medical device regulations. A comprehensive literature search 
was done from Google Scholar to determine the differences in drug 
and medical device development.
Results: Designing well-controlled prospective clinical trials of 
medical devices presents unique challenges that differ from those 
faced in studies of pharmaceuticals. Clinical outcomes observed in 
medical device studies, unlike drug trials, are influenced not only by 
the product under evaluation and the patient but also by the skill 
and discretion of the health care professional. Medically appropri-
ate alternative treatment regimens may not be available to provide 
randomized, concurrent controls in device trials. Because devices are 
often developed by small companies, financial constraints often limit 
the new product development and testing.
Conclusions: Medical device development is faced with unique chal-
lenges. Managing the design issues in clinical trials and complying 
with increasingly stringent regulatory guidelines is necessary to bring 
new devices faster to market with reduced cost.
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QualITy managemenT—neW peRSpecTIveS 
foR medIcal daTa manageR
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Increasingly, hospitals and other players in the health care sector will 
inevitably compete in terms of quality. Interinstitutional and cross-
sectoral quality assurance has been pushed forward during recent 
years. Institution-related outcomes are published and accessible to 
the public. Due to new health laws, in the near future, quality results 
of hospitals will not only be decisive for reimbursement increases or 
price reductions of the remuneration but will also be a crucial factor 
for a hospital’s survival. Hospitals that are not able to get quality 
deficiencies under control may lose their public supply mandate. 
Thus, the outcome of hospitals should be measured on the basis 
of predefined quality indicators to reach the objectives described 
earlier. Key indicators are, on the one hand, measures of medical 
performance. In particular, these include, for example, the type and 
numbers of surgical procedures as well as surgical complications in 
a certain time period. Also included are structural statistics about 
continuous medical education such as number of passed training 
courses for medical doctors and nurses. Moreover, information about 
patient safety are key indicators for quality assurance. Patient safety 
indicators, for example, are the number of patient falls and side 
effects of medication. These parameters have to be registered in a 
structured form and in a fixed frequency. The method to provide 
these indicators is a continuous comprehensive quality management, 
including capturing and monitoring of all relevant data. This requires 
the establishment of a professional operating system gaining all neces-
sary figures in daily clinical routine. Health information management 
